Histone deacetylase 1, Histone deacetylase 2, Histone deacetylase 3 (HDAC1, HDAC2, HDAC3)

Histone deacetylase 1, 2, and 3 (HDAC1, HDAC2, HDAC3) are zinc-dependent enzymes part of the class I histone deacetylase family. They catalyze the removal of acetyl groups from lysine residues on histone and numerous non-histone proteins, which promotes chromatin condensation and transcriptional repression. HDAC1 and HDAC2 predominantly localize to the nucleus and function in large corepressor complexes such as Sin3, NuRD, and CoREST, whereas HDAC3 associates with the SMRT/NCoR corepressor complex and displays dynamic nuclear-cytoplasmic shuttling[1][2][3][5][6]. Beyond transcriptional repression, HDAC1-3 regulate diverse biological processes, including cell cycle progression, development, metabolism, immune responses, and apoptosis[2][5]. Dysregulation of HDAC1-3 activity is implicated in cancer, neurodegenerative and cardiovascular diseases, inflammation, fibrosis, infection, and psychiatric disorders[3][4][6]. Several approved drugs target HDACs as anti-cancer agents by inhibiting their enzymatic activity, leading to increased histone acetylation and altered gene expression[2][6]. Therapeutic targeting is complicated by the widespread roles of HDAC1-3, resulting in significant on-target toxicities such as hematologic suppression, gastrointestinal side effects, and cardiac risks[6].

Other names

HD1RPD3HD1/2/3

Inhibition of histone deacetylation, leading to increased histone acetylation and chromatin relaxation, thereby enhancing gene transcription. Direct inhibition of HDAC catalytic activity. Some inhibitors are selective for HDAC1-3, others are pan-HDAC inhibitors.